As so far, the first human trial of TRPV4 antagonist GSK2798745 has completed its phase I trial (clinicaltrials.gov, NCT02119260), and the initial findings were promising and showed no significant safety concerns and serious adverse events related to this compound in healthy populations and patients with heart failure [118]. This evidence concerns the gene TRPV4 and heart failure.